Pharmaids Pharmaceuticals Limited (BOM:524572)
India flag India · Delayed Price · Currency is INR
39.87
+0.92 (2.36%)
At close: Feb 12, 2026

Pharmaids Pharmaceuticals Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
-132.67-107.77-79.68-75.561.450.93
Depreciation & Amortization
23.3324.417.250.170.080.45
Loss (Gain) From Sale of Assets
-30.450.960.20.31--
Asset Writedown & Restructuring Costs
--6.23---
Provision & Write-off of Bad Debts
--8.08---
Other Operating Activities
-36.56-42.96-69.47-23.52-0.04-0.05
Change in Accounts Receivable
-68.12-3.8923.577.012.77-2.77
Change in Inventory
-38.04-85.937.168.88-5.19-3.69
Change in Accounts Payable
111.5111.41-12.4-4.23-1.564.91
Change in Other Net Operating Assets
-9.89-36.15-7.1446.75-0.114.27
Operating Cash Flow
-180.89-139.91-106.2-40.19-2.594.05
Capital Expenditures
-108.35-124.81-228.63-16.73--0.02
Sale of Property, Plant & Equipment
196.152.191.47---
Cash Acquisitions
---524.83---
Investment in Securities
-1.15---32.7--
Other Investing Activities
11.362.392.08-4.67-
Investing Cash Flow
119.3-120.24-749.9-49.434.67-2.27
Long-Term Debt Issued
-326.9615.3---
Long-Term Debt Repaid
--56.67-24.56---
Net Debt Issued (Repaid)
70.68270.28-9.26---
Issuance of Common Stock
--780.12213.09--
Other Financing Activities
-39.4-36.73-24.26---
Financing Cash Flow
31.28233.56776.6213.09--
Miscellaneous Cash Flow Adjustments
--0--0--
Net Cash Flow
-30.31-26.6-79.5123.472.071.79
Free Cash Flow
-289.24-264.72-334.82-56.92-2.594.04
Free Cash Flow Margin
-116.57%-135.66%-218.84%--6.58%4.72%
Free Cash Flow Per Share
-7.67-7.51-14.74-4.41-0.250.39
Cash Interest Paid
19.717.0212.37---
Cash Income Tax Paid
0.590.63----
Levered Free Cash Flow
-247.26-184.11-302.47-81.63.373.54
Unlevered Free Cash Flow
-224.24-171.56-292.83-81.63.373.54
Change in Working Capital
-4.54-14.5511.1958.41-4.092.72
Source: S&P Global Market Intelligence. Standard template. Financial Sources.